Pharma companies at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
23 pharma companies are at ObesityWeek 2026 — 77 presentations on the program and 11 with a booth in the exhibit hall. Most represented: Eli Lilly (12 on the program), Novo Nordisk (11 on the program), Pfizer (5 on the program). 14 of them have their own page in this guide. As of Nov 12, 2026.
Topic
Top represented
Showing 1–4 of 23 organizations
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Eli Lilly Indianapolis, IN | ◆Platinum Sponsor |
Global medicine company working in diabetes, obesity and its long-term complications, Alzheimer's disease, immune disorders and hard-to-treat cancers. | Booth Exhibiting at Booth 509, 900, Suite 4, Suite 11, Suite 12, Suite 19, Suite 19a, Suite 19b, Suite 19c, Suite 19d, Suite 19e, Suite 27 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Sat Nov 14 12:00pm–1:00pm Women Inspiring and Elevating Leadership in Diabetes (WIELD): Pearls of Wisdom from Obesity Trailblazers Across Career Stages and Fields Women leaders from academia and industry share career-building strategies for trainees and established investigators, with time to network. Poster Sat Nov 14 7:30pm–8:30pm Eloralintide Added to Established Tirzepatide Enhanced Weight and Fat Loss in DIO Rats Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Significant Increases in SHBG Accompanying Weight Loss with Tirzepatide in the SURMOUNT Program Chronic disease and obesity complicationsMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Two-year HbA1c and Weight Outcomes by Tirzepatide Persistence Pattern in Type 2 Diabetes Metabolism and integrative physiology Talk Sun Nov 15 7:30am–8:30am Weight Management Foundayo Peer-led review of dosing, efficacy and safety for a once-daily oral obesity medicine for adults, with time for audience questions. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and food Poster Sun Nov 15 2:30pm–3:30pm Weight-Loss Targets for Predicting Glucose Normalization: SURMOUNT-1 176-Week Post-Hoc Analysis Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Patients Reported Orforglipron Was Simple, Convenient, Easy to Use: Results from the FOUNDERS Survey Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Reasons for Orforglipron Initiation and Treatment Goals: Results from the FOUNDERS Survey Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Phase 2 Study of Tirzepatide Plus Mibavademab Compared with Tirzepatide Alone in Adults With Obesity Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Loss with 18-Month Tirzepatide Use in Adults with Obesity and without Diabetes Obesity pharmacotherapy and drug developmentPolicy and public health Poster Sun Nov 15 2:30pm–3:30pm Healthcare Costs Trends with Tirzepatide Use in Treatment of Obesity: A Matched Cohort Analysis Obesity pharmacotherapy and drug developmentPolicy and public health Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Outcomes Among Zepbound (Tirzepatide) Users Engaging with the Lilly Health App Obesity pharmacotherapy and drug developmentInterventional and clinical studies Talk Sun Nov 15 3:30pm–3:45pm Talk Sun Nov 15 6:30pm–8:00pm One Patient, Many Perspectives: A Multidisciplinary Expert Roundtable on Obesity Care Specialists from primary care, cardiology, sleep medicine, surgery and other fields discuss one shared patient case to show how coordinated obesity care works. Metabolism and integrative physiologyInterventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceChronic disease and obesity complications Talk Mon Nov 16 7:00am–8:30am Beyond the Airway: Metabolic Drivers of Obstructive Sleep Apnea Small-group work through patient cases on how excess body fat contributes to obstructive sleep apnea, and on screening, diagnosis and treatment choices. Chronic disease and obesity complications Talk Mon Nov 16 7:15am–8:15am Seen Beyond the Scale: Addressing Weight Bias and Stigma in Pediatric Obesity Care Looks at how weight bias and stigma show up in pediatric care and gives clinicians ways to talk about weight respectfully with families. Pediatric and adolescent obesityClinical obesity care and professional practicePolicy and public health Talk Mon Nov 16 8:45am–9:00am Talk Mon Nov 16 11:45am–1:15pm Discover Zepbound (Tirzepatide) Injection Reviews efficacy, safety and dosing evidence for tirzepatide injection and how to identify adult patients who may be suitable for it. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 1:30pm–1:45pm Focus on Transitioning from Academia to Industry as Early Career Researcher Metabolism and integrative physiologyNeuroscience of appetite and eatingInterventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public health Poster Mon Nov 16 2:30pm–3:30pm Achieving Clinical Goals with Tirzepatide Treatment in the SURMOUNT-MAINTAIN Trial: A Post-hoc Analysis Pediatric and adolescent obesityObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm Poster Mon Nov 16 2:30pm–3:30pm |
Novo Nordisk Bagsværd, Denmark | ◆Platinum Sponsor |
Global healthcare company with a century of diabetes medicines, also treating obesity and rare blood and endocrine disorders, with its US arm in New Jersey. | Booth Exhibiting at Booth 309, 715, Suite 7, Suite 7a, Suite 7b Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 11:45am–1:15pm The Missing Piece in the Obesity Puzzle: Exploring the Immunobiology of Obesity and the Role of Amylin Explores obesity-related inflammation, how current drugs affect it, and evidence for emerging amylin-based therapies, including combined GLP-1 and amylin drugs. Metabolism and integrative physiologyClinical obesity care and professional practiceObesity pharmacotherapy and drug development Poster Sat Nov 14 7:30pm–8:30pm Real-World Weight Outcomes with Semaglutide 1.0, 1.7, and 2.4 mg in the US and UK (STEP ADAPT Real) Chronic disease and obesity complications Talk Sun Nov 15 9:45am–10:15am Evidence Snapshot: Addressing Weight and CV Risk in Patients with Obesity Reviews cardiovascular outcomes and chronic weight-management trial data in adults with overweight or obesity, with dosing and administration considerations. Interventional and clinical studiesClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complications Poster Sun Nov 15 2:30pm–3:30pm Cagrilintide’s Potential Benefits on Bone Health via Proteomics in Adults With Over-Weight or Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm AWS Cloud–First Data Discovery for Pragmatic Clinical Trial Linkage Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Preferences for Obesity Medications Among Health Care Professionals Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Obesity Medication Preferences Among Younger and Older Adults: An Age-Stratified Analysis Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Outcomes and Patient Experience with Oral Semaglutide in a Digital Support Cohort Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm 3-Month Food Noise and Patient-Reported Outcomes with Oral Semaglutide for Overweight or Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Characteristics of Early Initiators of Oral Semaglutide for Overweight or Obesity via Telehealth Obesity pharmacotherapy and drug developmentPolicy and public health Talk Sun Nov 15 6:30pm–9:00pm Obesity in Focus: Today's Evidence. Tomorrow's Possibilities. Speakers cover what has changed in obesity guidelines, evidence behind approved obesity drugs, and the biology of amylin and new amylin analog data. Interventional and clinical studiesClinical obesity care and professional practiceNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 11:30am–1:15pm The Evolution of Obesity Management: Incorporating a Maturing Science into Clinical Practice Case-based discussion of treating obesity as a lifelong chronic disease, with personalized drug choice, combination therapy and continued treatment. Clinical obesity care and professional practiceObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm The Predicted Impact of CagriSema on Cardiovascular Disease in US Adults With Overweight or Obesity Population health and epidemiologyNutrition, diet and food Poster Mon Nov 16 2:30pm–3:30pm Changes in Purchasing Behavior Following Initiation of GLP-1RAs: Data from a UK Consumer Panel Population health and epidemiologyNutrition, diet and food Poster Mon Nov 16 2:30pm–3:30pm Talk Mon Nov 16 5:00pm–5:15pm |
Pfizer New York, NY | ◇Bronze Sponsor |
Global drugmaker that discovers, develops and manufactures medicines and vaccines across many diseases. | Booth Exhibiting at Booth 601, Suite 20, Suite 20a, Suite 21, Suite 21a Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm NAD+ Augmentation via Nicotinamide Riboside Does Not Improve Cardiorespiratory Fitness in Aged Mice Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Monthly Berobenatide in Adults with Obesity/Overweight: VESPER-3 Cardiometabolic Risk Markers Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm A Multi‑omics View of Skeletal Muscle Responses to GLP‑1R Agonism in Obese Mice Metabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Effects of a Potent and Selective Small Molecule GIPR Antagonist in Preclinical Models of Obesity Interventional and clinical studies Poster Mon Nov 16 2:30pm–3:30pm Human-AI Co-Developed Algorithms for CGM-Based Meal Detection: New Paradigm for Digital Endpoints Nutrition, diet and foodPopulation health and epidemiology |
HP Hanmi Pharmaceutical Seoul, South Korea | |
Pharmaceutical company developing long-acting incretin drugs, including efpeglenatide and the triple agonist HM15275, plus muscle-preserving candidates. | Poster Sun Nov 15 2:30pm–3:30pm HM500197 Combination with Incretin-Based Therapy Preserves Skeletal Muscle Mass during Weight Loss Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm HM500197, a Long-Acting Peptide Based Myostatin Inhibitor, Improves Muscle Mass in Obese Mice Metabolism and integrative physiology Poster Mon Nov 16 2:30pm–3:30pm Efpeglenatide Attenuates Psoriasis in Both Obese and Lean Mice Chronic disease and obesity complications Poster Mon Nov 16 2:30pm–3:30pm HM15275, a GLP-1/GIP/Glucagon Triple Agonist, Shows Anti-tumor Efficacy in an Obesity-Associated CRC Chronic disease and obesity complications Poster Mon Nov 16 2:30pm–3:30pm Therapeutic Potential of HM15275, a Long-Acting GLP-1/GIP/Glucagon Triple Agonist, for Dyslipidemia Chronic disease and obesity complications |
Find buyers from pharma companies
Tell us what you sell and we’ll find the people at these pharma companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ObesityWeek 2026 by
Organization type
Topic
- Obesity pharmacotherapy and drug development 251
- Clinical obesity care and professional practice 196
- Interventional and clinical studies 231
- Metabolism and integrative physiology 217
- Nutrition, diet and food 164
- Pediatric and adolescent obesity 117
- Population health and epidemiology 156
- Chronic disease and obesity complications 224
- Neuroscience of appetite and eating 97
- Bariatric surgery and devices 58
- Policy and public health 102
Exhibit hall
Everyone
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction